JPRN-jRCT2031200445已完成2 期
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of ETC-1002 in Patients With Hypercholesterolemia
Matsumaru Takehisa0 个研究点目标入组 188 人开始时间: 2021年3月25日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 188
研究概览
简要总结
Superiority of ETC-1002 over placebo was verified in all treated groups, and the extent of LDL-C change from baseline at Week 12 was larger in the 120 mg group and the 180 mg group than in the 60 mg group. The safety profile of ETC-1002 was safe and tolerable in all ETC-1002 treated groups. There were no major differences in the safety profile of ETC-1002 between inadequate response to statins and statin-intolerant.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 < 75age old（—）
- 性别
- All
入选标准
- •1)Patients who have obtained informed consent to all of the observation/examination/evaluation items specified in the protocol
- •2)Patients must be on stable statin therapy defined as atorvastatin, pitavastatin, rosuvastatin, pravastatin, simvastatin, or fluvastatin daily[and other lipid-modifying therapies(LMTs) if needed] at least 4 weeks(6 weeks for fibrates) prior to screening and above LDL-C control target. Or Patients for statin intolerant must be on stable LMT(s) at least 4 weeks prior to screening and above LDL-C control target. Statin intolerance defined as an inability to tolerate 1 or more statins due to an adverse safety effect that started or increased during statin therapy and resolved or improved when statin therapy was discontinued or decreased. Patients on the lowest or under the dosage of the approved dose of statin or unable to tolerate any statin at any dose were eligible. Patients could continue taking the lowest or under the dosage of the approved dose of statin therapy or taking other LMTs throughout the study provided that it was stable and well tolerated.
- •3)Fasting mean TG level < 400 mg/dL from measurements at screening
排除标准
- •1)Women who are pregnant or breastfeeding or who have a positive pregnancy test (urine) result at screening or baseline visits
- •2)Sexually active male subjects or sexually active female subjects of childbearing potential who do not agree to practice 2 different methods of birth control or to remain abstinent during the trial and for 30 days after final IMP administration test (urine) result at screening or baseline visits
- •3)Patients with homozygous familial hypercholesterolemia (HoFH)
- •4)Patients with a history or current symptoms of any of the following clinically significant cardiovascular diseases within 3 months prior to screening or before baseline visit
- •-Myocardial infarction, severe or unstable angina pectoris, coronary angioplasty, coronary artery bypass graft, stroke, transient ischemic attack, symptomatic carotid artery stenosis, symptomatic peripheral arterial disease, or decompensated heart failure
- •-Abdominal aortic aneurysm
- •-Unexplained syncope or long-QT syndrome, family history of long-QT syndrome, or risk factors for Torsade de Pointes, such as persistent hypokalemia or second- or third-degree atrioventricular block (except when controlled by medication, etc)
- •5)Uncontrolled hypertension, defined as follows:
- •-Sitting systolic blood pressure after resting 5 minutes of>=160 mmHg or diastolic blood pressure of >=100 mmHg at screening
- •6)Patients with uncontrolled and serious hematologic or coagulation disorders or with Hgb of <10.0 g/dL at screening
- •7)Patients with type 1 diabetes or uncontrolled type 2 diabetes with hemoglobin A1c (HbA1c) of >=9% at screening
- •8)Patients with uncontrolled hypothyroidism with thyroid-stimulating hormone (TSH) of >1.5x ULN at screening
- •9)Patients with liver disease or dysfunction, including:
- •-Positive serology for hepatitis B surface antigen (HBsAg) and/or hepatitis C antibodies at screening
- •-Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) of>=3xULN and/or total bilirubin of>=2xULN
- •10)Patients with creatine kinase (CK) elevation( >3xULN) at screening
- •11)Patients with renal dysfunction or nephritic syndrome or a history of nephritis and with estimated glomerular filtration rate (eGFR) of =<30 mL/min/1.73m2 at screening
研究者
相似试验
已完成
2 期
A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 DiabetesType 2 DiabetesHyperlipidemiaNCT01607294Esperion Therapeutics, Inc.60
已完成
3 期
A Confirmatory Trial of ETC-1002 in Patients With Hyper-LDL CholesterolemiaHyper-low-density Lipoprotein (LDL) CholesterolemiaNCT05683340Otsuka Pharmaceutical Co., Ltd.96
已完成
2 期
A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With HypercholesterolemiaHypercholesterolemiaNCT01779453Esperion Therapeutics, Inc.58
已完成
2 期
Evaluation of ETC-1002 in Participants With Hypercholesterolemia and HypertensionHypertensionHypercholesterolemiaNCT02178098Esperion Therapeutics, Inc.143
已完成
2 期
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated TriglyceridesDyslipidemiaNCT01262638Esperion Therapeutics, Inc.177